Celgene Corporation (CELG): Today's Featured Drugs Winner

Celgene Corporation ( CELG) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.1%. By the end of trading, Celgene Corporation rose 63 cents (0.9%) to $70.77 on average volume. Throughout the day, 2.8 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of three million shares. The stock ranged in a price between $69.18-$70.83 after having opened the day at $69.65 as compared to the previous trading day's close of $70.14. Other companies within the Drugs industry that increased today were: Arena Pharmaceuticals ( ARNA), up 25.7%, Savient Pharmaceuticals ( SVNT), up 16.7%, K-V Pharmaceutical Company ( KV.B), up 11.7%, and Theratechnologies ( THER), up 11.3%.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes various therapies to treat cancer and immune-inflammatory related diseases primarily in the United States and Europe. Celgene Corporation has a market cap of $30.75 billion and is part of the health care sector. The company has a P/E ratio of 21.7, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Shares are up 3.3% year to date as of the close of trading on Monday. Currently there are 21 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and six rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the negative front, Dendreon ( DNDN), down 25.1%, Complete Genomics ( GNOM), down 16.4%, Insmed ( INSM), down 15.1%, and Alexza Pharmaceuticals ( ALXA), down 8.3%, were all losers within the drugs industry with Bristol-Myers Squibb Company ( BMY) being today's drugs industry loser.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

If you liked this article you might like

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

Apple Is the Tom Brady of Stocks: Cramer's 'Mad Money' Recap (Thursday 8/31/17)

Cramer: Fantasy Shmantasy -- Let's Get Real With These Stock Picks